In vivo and in vitro evaluation of the mutagenic potential of carbamazepine: does melatonin have antimutagenic activity?
MJFCT-Mansoura Journal of Forensic Medicine and Clinical Toxicology. 1997; 5 (1): 47-65
in English
| IMEMR
| ID: emr-46121
ABSTRACT
The mutagenic potential of carbamazepine [CBZ] therapy has been evaluated invivo and in vitro. Analysis of chromosome aberrations [CA], sister chromatidexchanges [SCEs], mitotic and proliferation [PRI] indices were performed. Thein vivo was carried out on 30 patients with idiopathic epilepsy and undergoingtreatment with CBZ for different periods starting from 6 months up to 15years. Plasma CBZ levels were also determined for each patient. From theobserved results, it was suggested that CBZ monotherapy may lead to chromosomedamaging effects [genotoxic] and the use of melatonin as anti- mutagenic agentfor human protection against CBZ-induced chromosome damage should beconsidered
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Chromosome Aberrations
/
Protective Agents
/
Cytogenetic Analysis
/
Melatonin
/
Mitotic Index
/
Anticonvulsants
/
Mutagens
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Mansoura J. Forensic Med. Clin. Toxicol.
Year:
1997
Similar
MEDLINE
...
LILACS
LIS